• CN
    News & Events

    News & Events

    Chipscreen Highlights: Stay Updated on Recent Hot Topics

    Select year

    2026 2025 2024 2023 2022 Earlier
    shown/page
    15
    5 10 15 20

    2025.10.15

    ESMO 2025 | Study Results on Chidamide's HDACi+IO Strategy Selected for Proffered Paper Session
    ESMO 2025 | Study Results on Chidamide's HDACi+IO Strategy Selected for Proffered Paper Session

    Full text

    2025.09.25

    Leading with Source Innovation: Chipscreen Biosciences and Chiglitazar Sodium (Bilessglu®) Honored with A Decade of Glory for China's Innovative Drugs Awards
    Leading with Source Innovation: Chipscreen Biosciences and Chiglitazar Sodium (Bilessglu®) Honored with A Decade of Glory for China's Innovative Drugs Awards

    Full text

    2025.08.18

    Chipscreen Biosciences 2025 Innovation Summit Concludes Successfully: AI + Integrated Core Technology Platform Fuels Original New Drug Development
    Chipscreen Biosciences 2025 Innovation Summit Concludes Successfully: AI + Integrated Core Technology Platform Fuels Original New Drug Development

    Full text

    2025.08.07

    International Hepatology Journal Publishes Key Study on Chiglitazar Sodium (Bilessglu®) for MASH Treatment
    International Hepatology Journal Publishes Key Study on Chiglitazar Sodium (Bilessglu®) for MASH Treatment

    Full text

    2025.07.31

    Chipscreen Biosciences' Brain-Penetrant Aurora B Selective Inhibitor CS231295 Tablet Receives FDA IND Approval, Advancing Global Clinical Development
    Chipscreen Biosciences' Brain-Penetrant Aurora B Selective Inhibitor CS231295 Tablet Receives FDA IND Approval, Advancing Global Clinical Development

    Full text

    2025.07.27

    ESMO 2025丨Chidamide HDAC+IO Study Selected for Featured Presentation
    ESMO 2025丨Chidamide HDAC+IO Study Selected for Featured Presentation

    Full text

    2025.07.09

    A Milestone in First-Line DLBCL Treatment! Topline Results from Chidamide DEB Study Achieve Primary EFS Endpoint
    A Milestone in First-Line DLBCL Treatment! Topline Results from Chidamide DEB Study Achieve Primary EFS Endpoint

    Full text

    2025.05.31

    ASCO 2025 Highlight | Complete Response Rate Surpasses 95%! Chidamide Combination Therapy Shows Promising Results in Oral Presentation for Untreated NK/T-Cell Lymphoma
    ASCO 2025 Highlight | Complete Response Rate Surpasses 95%! Chidamide Combination Therapy Shows Promising Results in Oral Presentation for Untreated NK/T-Cell Lymphoma

    Full text

    2025.05.15

    Chidamide (Epidaza®) - 19 studies to be presented at EHA 2025
    Chidamide (Epidaza®) - 19 studies to be presented at EHA 2025

    Full text

    2025.04.18

    CSCO Guidelines Major Update for First-line DLBCL: Epidaza® Receives First Authoritative Recommendation
    CSCO Guidelines Major Update for First-line DLBCL: Epidaza® Receives First Authoritative Recommendation

    Full text

    2025.03.11

    AI + Chipscreen Biosciences | Technology Empowerment for Innovative Drug Development
    AI + Chipscreen Biosciences | Technology Empowerment for Innovative Drug Development

    Full text

    2024.11.18

    Major NRDL Update｜Chipscreen’s Epidaza® Becomes the Only Oral Novel Drug for First-Line DLBCL, while Bilessglu® Retains Listing at Current Price
    Major NRDL Update｜Chipscreen’s Epidaza® Becomes the Only Oral Novel Drug for First-Line DLBCL, while Bilessglu® Retains Listing at Current Price

    Full text

    2024.10.17

    Chipscreen Biosciences' Innovative Anti-Tumor Drug CS231295 Tablets： Investigational New Drug (IND) Application Accepted
    Chipscreen Biosciences' Innovative Anti-Tumor Drug CS231295 Tablets： Investigational New Drug (IND) Application Accepted

    Full text

    2024.10.15

    Chiglitazar for the Treatment of MASH Phase II Clinical Study Selected for Oral Presentation at the 2024 American Liver Disease Annual Meeting
    Chiglitazar for the Treatment of MASH Phase II Clinical Study Selected for Oral Presentation at the 2024 American Liver Disease Annual Meeting

    Full text

    2024.07.23

    NMPA Approves Phase III Clinical Trial Application for Chipscreen’s Class I Innovative Anti-Tumor Drug Chidamide in Colorectal Cancer Treatment
    NMPA Approves Phase III Clinical Trial Application for Chipscreen’s Class I Innovative Anti-Tumor Drug Chidamide in Colorectal Cancer Treatment

    Full text
    Media contact

    Media contact

    • Media contact

      （+86）0755-36993500

    • Media contact

      pr@juliucq.com